By Fineline Cube Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that China’s National Medical Products Administration (NMPA) has accepted its National Drug Application (NDA) for HRG2010, intended for the treatment of Parkinson’s disease — a key regulatory step for the company’s next‑generation levodopa/carbidopa combination candidate.
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) |
| Agency | National Medical Products Administration (NMPA), China |
| Filing | National Drug Application (NDA) accepted |
| Asset | HRG2010 (Class 2 innovative drug) |
| Indication | Parkinson’s disease |
| Announcement Date | 24 Aug 2026 |
Drug Profile & Formulation
- Classification: Class 2 innovative drug, independently developed by Hengrui
- Composition: Fixed‑dose combination of levodopa and the peripheral decarboxylase inhibitor carbidopa
- Design Advantage: Engineered with an optimized release mechanism to achieve rapid onset alongside prolonged and stable efficacy — addressing the wearing‑off phenomenon common with standard levodopa/carbidopa regimens
- Comparable Marketed Products: Carbidopa/levodopa sustained‑release tablets (Sinemet), Amneal Pharmaceuticals’ RYTARY (IPX006) and CREXONT (IPX203) — both globally and domestically
Clinical Evidence – Confirmatory Phase III Study (HRG2010‑301)
| Endpoint / Metric | Result (HRG2010 vs. Control) |
|---|---|
| “OFF” Time | Significantly reduced |
| Good “ON” Time | Significantly extended |
| Study Population | Parkinson’s disease patients experiencing motor fluctuations |
| Long‑Term Efficacy | Maintained over the study period |
| Safety Profile | Consistent with known carbidopa/levodopa characteristics; no new safety signals |
The Phase III results demonstrate that HRG2010 capsules significantly reduced “OFF” time and extended good “ON” time compared with the control group, with long‑term efficacy maintained. On safety, the profile aligned with the established characteristics of carbidopa/levodopa combination therapies, with no new safety signals observed.
Strategic Outlook
- Large Unmet Need: Motor fluctuations — including “OFF” episodes — remain a central challenge in long‑term Parkinson’s management, making therapies that stabilize “ON” time highly valued clinically and commercially.
- Competitive Positioning: Against global benchmarks such as RYTARY and CREXONT, HRG2010’s optimized release design positions Hengrui to compete for a meaningful share of China’s Parkinson’s disease market.
- Portfolio Expansion: The NDA acceptance reinforces Hengrui’s strategy of broadening beyond oncology into large chronic disease franchises with high commercial durability.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the regulatory review timeline, clinical outcomes and commercial prospects of HRG2010. Actual results may differ due to risks including NMPA review decisions, market adoption and competitive dynamics.-Fineline Info & Tech